InStride Health

Massachusetts-based InStride Health offers insurance-based access to specialty pediatric anxiety/OCD outpatient treatment program for children, teens and young adults (ages 7-22). The company accepts most major insurance plans in the states it serves. Its treatment methodology includes taking care outside the office and into the environments where individual fears and anxieties exist, helping to accelerate learning and build resilience.

Their patients benefit from evidence-based therapies such as CBT, ACT, and DBT components, focusing on exposure and delivered by a unified team consisting of a psychiatrist, therapist, and coach. The care provided starts with frequent interactions that decrease over time. The company’s services include individual and family therapy, specialized groups for children and their parents or caregivers, exposure coaching on a scheduled basis or as needed, and medication management. The company uses Measurement-Based Care (MBC) to maintain data-driven transparency and accountability. InStride treatment is entirely virtual, proven to be as effective as face-to-face treatment for young people with anxiety and/or OCD.

Funding and financials

In March 2024, InStride Health secured USD 30 million in a series B funding round led by General Catalyst. The company expected to use the funds to enhance the clinical quality of InStride Health and to expand into new markets.